Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2017’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)

The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects

The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Atox Bio Ltd

Cellmid Ltd

Complexa Inc

DiaMedica Therapeutics Inc

DURECT Corp

Evotec AG

Exponential Biotherapies Inc

F. Hoffmann-La Roche Ltd

G1 Therapeutics Inc

Kringle Pharma Inc

Mitotech SA

NephroGenex Inc

NeuroVive Pharmaceutical AB

Nyken BV

ProMetic Life Sciences Inc

Quark Pharmaceuticals Inc

Regulus Therapeutics Inc

SBI Pharmaceuticals Co Ltd

Spherium Biomed SL

STATegics Inc

Stealth BioTherapeutics Inc

Thrasos Therapeutics Inc

Torrent Pharmaceuticals Ltd

Xigen SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development

A1M Pharma AB

Alloksys Life Sciences BV

Am-Pharma BV

Angion Biomedica Corp

Atox Bio Ltd

Cellmid Ltd

Complexa Inc

DiaMedica Therapeutics Inc

DURECT Corp

Evotec AG

Exponential Biotherapies Inc

F. Hoffmann-La Roche Ltd

G1 Therapeutics Inc

Kringle Pharma Inc

Mitotech SA

NephroGenex Inc

NeuroVive Pharmaceutical AB

Nyken BV

ProMetic Life Sciences Inc

Quark Pharmaceuticals Inc

Regulus Therapeutics Inc

SBI Pharmaceuticals Co Ltd

Spherium Biomed SL

STATegics Inc

Stealth BioTherapeutics Inc

Thrasos Therapeutics Inc

Torrent Pharmaceuticals Ltd

Xigen SA

Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles

(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A1M-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CXA-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DM-199 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Kidney Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DUR-928 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EA-230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elamipretide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVP-019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYK-1341 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4419 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Plastomitin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pyridoxamine Dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-190 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Human Alkaline Phosphatase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RLS-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RMC-035 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-6839328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-15016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STSE-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRC-160334 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vanadis-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects

Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products

Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones

Featured News & Press Releases

Feb 10, 2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies

Jan 31, 2017: Angion Biomedica Phase 2 “GUARD” Clinical Trial of BB3 in Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study in Renal Transplant Recipients with Delayed Graft Function

Jan 30, 2017: DURECT Announces Update on DUR-928 Development Program

Dec 20, 2016: Silence Therapeutics Announces Quark Arbitration Resolution

Dec 09, 2016: ROSGard shows renal protective effect during radiation therapy

Nov 07, 2016: Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016

Sep 19, 2016: Quark Pharmaceuticals to provide an update on kidney transplant drug QPI-1002

Sep 13, 2016: A1M Pharma selects kidney protection in connection with cancer treatment as their first indication within acute kidney injury

May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial

Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury

Apr 19, 2016: AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design”

Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002

Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)

Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928

Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by A1M Pharma AB, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Alloksys Life Sciences BV, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Am-Pharma BV, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Angion Biomedica Corp, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Atox Bio Ltd, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Cellmid Ltd, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Complexa Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by DiaMedica Therapeutics Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by DURECT Corp, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Evotec AG, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Exponential Biotherapies Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by G1 Therapeutics Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Kringle Pharma Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Mitotech SA, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by NephroGenex Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by NeuroVive Pharmaceutical AB, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Nyken BV, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by ProMetic Life Sciences Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Quark Pharmaceuticals Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Rediscovery Life Sciences, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Regulus Therapeutics Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Spherium Biomed SL, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by STATegics Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Stealth BioTherapeutics Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Thrasos Therapeutics Inc, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline by Xigen SA, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Dormant Projects, H1 2017

Acute Renal Failure (ARF) (Acute Kidney Injury) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports